Market reviews 2013

Market review on human pharmaceuticals 2013

Published on 4 February 2014

According to IMS Health pharmaceutical sales statistics (previously Finnish Pharmaceutical Data Ltd), Finnish wholesale of human pharmaceuticals in 2013 was up by 2% on the previous year at EUR 2,067 (2,031) million.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales faster than the markets as a whole and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in 2013 amounted to EUR 233 (219) million, up by 6% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets grew slightly and was 11% (11%).

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2013 the total sales of Parkinson’s drugs in the United States were up by 5% at USD 791 million (USD 751 million in the previous 12-month period). The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs totalled EUR 979 (955) million in the 12-month period ending in September 2013, and the average market growth was 3%. In Japan sales of Parkinson’s drugs were down by 11% at EUR 523 (584) million.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2013 the total sales of Parkinson’s drugs containing entacapone were USD 163 (196) million in the United States and EUR 153 (156) million in the five largest European markets.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about one-fifth of the Group’s net sales. Sales of these products clearly decreased in the United States and slightly decreased in Europe. In Japan sales grew slightly better than the market as a whole. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2013, sales of Orion’s branded Parkinson’s drugs in the United States were down by 71% at USD 48 (162) million. Sales were down by 3% at EUR 151 (156) million in the five largest markets in Europe, and in Japan sales were EUR 59 (66) million. The market share of Orion’s branded Parkinson’s drugs was 6% in the United States, on average 16% in the five largest European markets and 11% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Orion’s Precedex® intensive care sedative (dexmedetomidine) were up by 30% at USD 323 million in the 12-month period ending in September 2013 (USD 249 million in the previous 12-month period). About four-fifths of the sales amounting to USD 264 (195) million were in the United States, where Precedex sales grew by 36%.

According to IMS Health pharmaceutical sales statistics, total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in Europe in the 12-month period ending in September 2013 were EUR 476 (471) million. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2013 sales of Orion’s dexdor® intensive care sedative (dexmedetomidine) were up by 143% at EUR 20 (8) million in Europe.

 

Published on 22 October 2013

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–September 2013 totalled EUR 1,520 (1,489) million.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales faster than the markets as a whole and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in January–September 2013 amounted to EUR 172 (162) million, up by 7% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 11% (11%).

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2013 the total sales of Parkinson’s drugs in the United States were up by 8% at USD 791 million (USD 731 million in the previous 12-month period). The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs totalled EUR 969 (951) million, and the average market growth was 2%. In Japan sales of Parkinson’s drugs declined by 2% to EUR 553 (562) million.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2013 the total sales of Parkinson’s drugs containing entacapone were USD 175 (193) million in the United States and EUR 153 (156) million in the five largest European markets.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about a quarter of the Group’s net sales. In the United States sales of these products clearly decreased. In Europe sales remained similar to the comparative period, and in Japan sales continued to grow well and clearly better than the market as a whole. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2013, sales of Orion’s branded Parkinson’s drugs in the United States were down by 60% at USD 71 (177) million. Sales were EUR 152 (156) million in the five largest markets in Europe, and EUR 63 (62) million in Japan. The market share of Orion’s branded Parkinson’s drugs was 9% in the United States, on average 16% in the five largest European markets and 11% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Orion’s Precedex® intensive care sedative (dexmedetomidine) were up by 39% at USD 321 million in the 12-month period ending in June 2013 (USD 231 million in the previous 12-month period). About four-fifths of the sales amounting to USD 262 (180) million were in the United States, where Precedex sales grew by 46%.

According to IMS Health pharmaceutical sales statistics, total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) were in Europe in the 12-month period ending in June 2013 at EUR 474 (475) million. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending inJune 2013 sales of Orion’s dexdor® intensive care sedative (dexmedetomidine) were up by 259% to EUR 18 (5) million in Europe.

 

Published on 30 July 2013

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–June 2013 totalled EUR 1,010 (1,000) million.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales faster than the markets as a whole and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in January–June 2013 amounted to EUR 116 (108) million, up by 7% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 11% (11%).

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2013 the total sales of Parkinson’s drugs in the United States were up by 10% at USD 783 million (USD 715 million in the previous 12-month period). The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs totalled EUR 965 (949) million, and the average market growth was 2%. In Japan sales of Parkinson’s drugs grew by 9% to EUR 580 (533) million.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2013 the total sales of Parkinson’s drugs containing entacapone were USD 188 (191) million in the United States and EUR 155 (156) million in the five largest European markets.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about a quarter of the Group’s net sales. In the United States sales of these products clearly decreased. In Europe sales remained similar to the comparative period, and in Japan sales continued to grow well and clearly better than the market as a whole. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2013, sales of Orion’s branded Parkinson’s drugs in the United States were down by 49% at USD 96 (191) million. Sales were EUR 154 (156) million in the five largest markets in Europe, and grew by 14% to EUR 66 (58) million in Japan. The market share of Orion’s branded Parkinson’s drugs was 12% in the United States, on average 16% in the five largest European markets and 11% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Orion’s Precedex® intensive care sedative (dexmedetomidine) were up by 39% at USD 301 million in the 12-month period ending in March 2013 (USD 217 million in the previous 12-month period). About four-fifths of the sales amounting to USD 242 (168) million were in the United States, where Precedex sales grew by 44%.

According to IMS Health pharmaceutical sales statistics, total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) were down by 2% in Europe in the 12-month period ending in March 2013 at EUR 472 (483) million. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2013 sales of Orion’s dexdor® intensive care sedative (dexmedetomidine) were up by 530% to EUR 15 (2) million in Europe.

 

Published on 23 April 2013

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–March 2013 totalled EUR 497 (493) million.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales faster than the markets as a whole and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in January–March 2013 amounted to EUR 57 (54) million, up by 7% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 12% (11%).

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in December 2012 the total sales of Parkinson’s drugs in the United States were up by 8% at USD 771 million (USD 716 million in the previous 12-month period). The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs totalled EUR 963 (954) million, and the average market growth was 1%. In Japan sales of Parkinson’s drugs grew by 13% to EUR 593 (523) million.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in December 2012 the total sales of Parkinson’s drugs containing entacapone were USD 197 (191) million in the United States and EUR 157 (156) million in the five largest European markets.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about a quarter of the Group’s net sales. In the United States sales of these products decreased. In Europe sales increased slightly, and in Japan sales continued to grow well and clearly better than the market as a whole. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in December 2012, sales of Orion’s branded Parkinson’s drugs in the United States were down by 30% at USD 134 (191) million. Sales were EUR 157 (156) million in the five largest markets in Europe, and grew by 21% to EUR 67 (56) million in Japan. The market share of Orion’s branded Parkinson’s drugs was 17% in the United States, on average 16% in the five largest European markets and 11% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Orion’s Precedex® intensive care sedative (dexmedetomidine) were up by 31% at USD 270 million in the 12-month period ending in December 2012 (USD 206 million in the previous 12-month period). About four-fifths of the sales amounting to USD 213 (161) million were in the United States, where Precedex sales grew by 32%.

According to IMS Health pharmaceutical sales statistics, total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) were down by 3% in Europe in the 12-month period ending in December 2012 at EUR 474 (489) million. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in December 2012 sales of Orion’s dexdor® intensive care sedative (dexmedetomidine) were EUR 12 million in Europe.